UG Healthcare Corporation Ltd - Another blockbuster quarter

8 Feb 2021
  • 1H21 PATMI jumped 64x YoY to S$54.9mn as revenue tripled to S$159mn, beating our forecast by 22%.
  • Gross margins leapt from 18% to 62% YoY as selling prices rose more than 1.5x to S$117 per 1,000 pieces. UG sells both nitrile and latex gloves.
  • Maintain BUY. We raise FY21e PATMI by 28% to S$107.8mn to account for higher glove selling prices and margins. Our target price remains pegged at a 30% PE discount to the Big 4 glove makers’ FY22e valuations. As rubber glove valuations have compressed to around 10x PE, our target PE for FY22e drops from 14x to 7x. This lowers our TP from S$1.35 to S$1.03.

 

Positives

+ Higher selling price drove revenue growth. 1H21 revenue tripled YoY to S$159mn with an estimated 20% growth in volume and 1.5x jump in prices. Sales to China spiked 457% YoY as customers stocked up ahead of winter and the festive season.

+ Gross margins remained robust. 1H21 gross margin was 62%, triple that of 1H20 as glove prices skyrocketed. QoQ, margins expanded from 60.6% in 1Q21 to 63.6% in 2Q21.

+ Record earnings bolstered cash. Cash from operations rose to S$45.9mn. The company now has net cash of S$32.5mn, a major reversal from net debt of S$37mn a year ago. UG announced a special DPS of S$0.00105 and a total payout of S$0.645mn.

 Negative

– Some lag in deliveries and higher costs. There have been shipment delays. As a result, inventories almost doubled in the past six months to S$57mn. Inventories were predominantly finished goods on transit to Europe. Container constraints are expected to ease only after February. Shipping rates to Europe have catapulted almost 5-fold to around US$10,000 per container. Even then, shipping rates only account for around 2% of UG’s selling prices.

Outlook

Earnings are still expected to grow QoQ as prices continue to climb in 2021. We also see other growth drivers for UG even if glove prices taper off. Firstly, production capacity will expand by 35% YoY to 4.6bn pieces in FY22e. Secondly, exposure to emerging markets and low penetration rates could provide sources of growth.

 

Other updates:

  • ASPs for nitrile and latex gloves are around US$130-140 and US$90-95 per 1,000 pieces respectively. Demand is still outstripping supply. Latex prices can climb faster in 2021, driven by emerging markets.
  • Securing sufficient foreign workers will be a priority if UG expands further. Every week, workers have to undergo COVID-19 antigen tests.
  • UG’s pricing policy is not to “max out” prices to customers. It emphasises supporting long-term dedicated customers during this period of tight supply.
  • UG’s priority is to conserve cash for expansion that requires new land and downstream capacity such as warehouses.
  • Nitrile raw material prices are starting to stabilise.
  • An additional 500mn of capacity to 3.4bn pieces will come on stream in April 2021. A new 1.2bn capacity plant is under construction with commissioning expected in 1Q22 (Jul-Sep 2022). UG is studying plans for expanding above 4.6bn.

Maintain BUY with lower target price of S$1.03, from S$1.35

We continue to value UG at a 30% discount to the Big 4 glove makers. Historically, UG’s discount was around 40%. As industry valuations have corrected to around 10x PE, our target PE for FY22e drops from 14x to 7x. This lowers our TP from S$1.35 to S$1.03.

We raise FY21e PATMI by 28% to S$107.8mn to account for the continuous rise in its ASPs and margins. Our FY22e PATMI assumes a 24% YoY contraction in ASPs to around S$80 per 1,000 gloves. We also assume a 15% increase in production costs in FY22e.

About the author

Paul Chew
Head of Research
Phillip Securities Research Pte Ltd

Paul has 20 years of experience as a fund manager and sell-side analyst. During his time as fund manager, he has managed multiple funds and mandates including capital guaranteed, dividend income, renewable energy, single country and regionally focused funds.

He graduated from Monash University and had completed both his Chartered Financial Analyst and Australian CPA programme.

Latest Reports

Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you

IMPORTANT INFORMATION

This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  

 

Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com